/
Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware, where we conduct discovery, clinical development and commercial operations.
Margins and capital returns are both well above average: 29.46% operating margin, ROIC at 26.05%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 21.2% YoY with margins expanding 28.0pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$5.36B
▲ +21.2% YoY
Net Income (TTM)
$1.43B
▲ +3845.0% YoY
Op. Margin
30.05%
▲ +28.0pp YoY
ROIC
25.64%
▲ +24.9pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
$1.52B
▲ +321.5% YoY
Net Debt
-$3.98B
Net Cash Position
Cash & Equiv.
$4.02B
5Y CAGR: +14.0%
Continue Research